EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische Studie

Upadacitinib effectiveness in moderate‐to‐severe atopic dermatitis: A real‐life multicentre and retrospective study

F Javier Melgosa Ramos iD, Víctor González-Delgado iD, José María Sánchez Motilla, Galarreta Pascual Marta, Almudena Mateu Puchades, Santos Alarcón Sergio

Australasian Journal of Dermatology · 2023

DOI: 10.1111/ajd.14164 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Australasian Journal of Dermatology, 2023. Verfasst von F Javier Melgosa Ramos und 5 weiteren Autor:innen. Beteiligte Einrichtung: University Hospital Doctor Peset of Valencia, Valencia, Spain. Hauptthemen laut MEDLINE: Dermatitis, Atopic. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 13 Literaturangaben. Gefördert von: AbbVie.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This was an observational and retrospective multicentre study conducted on adolescents and adults diagnosed with moderate‐to‐severe atopic dermatitis (AD) and treated with upadacitinib. Disease severity was measured by Eczema Area and Severity Index (EASI), validated investigator global assessment for AD and pruritus Numerical Rating Scale (NRS) at baseline and Weeks 4, 16, 24 and 52 (when available). Twenty‐one patients were included. All patients had previously received topical and systemic corticosteroids. Rapid response to upadacitinib was observed: Mean (SD) EASI score was 19.8 (6.5) at baseline, and 3.1 (4.2), 0.9 (1.4), 0.6 (0.6) and 0.6 (0.6) at the Weeks 4, 16, 24 and 52, respectively. Itch was controlled at Week 4 in all patients (mean [SD] NRS score 7.6 [1.9] baseline, 1.5 [1.3] W4). Severe infections or major adverse cardiovascular events were not reported. We highlight effectiveness and rapid response of upadacitinib in achieving itch control even in long‐standing recalcitrant cases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicAdultAdolescentHumansRetrospective StudiesSeverity of Illness IndexHeterocyclic Compounds, 3-RingPruritusTreatment OutcomeDouble-Blind Method

Stichwörter der Autor:innen

JAK inhibitorsatopic dermatitisreal-world evidence

Substanzen

upadacitinibHeterocyclic Compounds, 3-Ring

Autor:innen und Institutionen

  • University Hospital Doctor Peset of Valencia, Valencia, Spain.
  • Clinic University Hospital of Valencia, Valencia, Spain.
  • University Hospital Virgen de los Lirios, Alcoy, Spain.

ORCID-Profile: F Javier Melgosa Ramos, Víctor González-Delgado

Förderung

  • AbbVie

Zitieren

APA

Melgosa Ramos, F. J., González-Delgado, V., Motilla, J. M. S., Marta, G. P., Mateu Puchades, A., & Sergio, S. A. (2023). Upadacitinib effectiveness in moderate‐to‐severe atopic dermatitis: A real‐life multicentre and retrospective study. Australasian Journal of Dermatology. https://doi.org/10.1111/ajd.14164

Vancouver

Melgosa Ramos FJ, González-Delgado V, Motilla JMS, Marta GP, Mateu Puchades A, Sergio SA. Upadacitinib effectiveness in moderate‐to‐severe atopic dermatitis: A real‐life multicentre and retrospective study. Australasian Journal of Dermatology. 2023. doi:10.1111/ajd.14164

BibTeX
@article{MelgosaRamos2023,
  author = {Melgosa Ramos, F Javier and González-Delgado, Víctor and Motilla, José María Sánchez and Marta, Galarreta Pascual and Mateu Puchades, Almudena and Sergio, Santos Alarcón},
  title = {Upadacitinib effectiveness in moderate‐to‐severe atopic dermatitis: A real‐life multicentre and retrospective study},
  journal = {Australasian Journal of Dermatology},
  year = {2023},
  doi = {10.1111/ajd.14164}
}
Kostenlos starten →